February 3, 2009 -
Reaxys(TM) is based on information from Elsevier industry chemistry databases (CrossFire Beilstein, CrossFire Gmelin, and Patent Chemistry Database), merged together to promote R/D efficiency. With interface optimized for clear results visualization, Web-based solution provides workflow and decision making support for synthesis design and planning to help synthetic scientists efficiently gather relevant information. Access to key data is likewise accelerated via tabulated overview.
New 'Reaxys' Solution Improves Workflow Quality and Efficiency for Chemists
FRANKFURT, Germany, January 26 --
- Elsevier's New Web-Based Solution Combines Content From the Trusted CrossFire Databases in a Highly Intuitive and Easy to use Interface With New Features and Functionality
Elsevier, the leading publisher of scientific, medical and technical products and services, today introduced Reaxys, a new workflow solution for synthetic chemists. Reaxys is based on data from Elsevier's industry leading chemistry databases (CrossFire Beilstein, CrossFire Gmelin and Patent Chemistry Database) now merged together to provide harmonized content, additional functionalities and a redesigned interface to help improve R&D efficiency. Reaxys also contains new unique features including a synthesis planner and advanced results handling to help scientists gather relevant information more efficiently.
"Scientists, both in academia and industry, are under increasing pressure to deliver more and better results in a shorter time and make research decisions faster," said Mark van Mierle, managing director for Elsevier Information Systems. "Reaxys now gives them a tool to quickly create an overview of the of synthesis design options available for their work, research and quickly identify and select the most appropriate. By integrating chemical reaction and substance data from trusted sources with a synthesis design process, customers can accelerate early phase discovery."
Features include:
- Workflow and decision making support for synthesis design and planning, e.g. by comparing alternative synthesis routes and selecting the most relevant paths;
- Quick access to key data by displaying results in a unique tabulated overview of the most important information;
- Convenient and flexible output of data in most common formats.
Reaxys has been developed with input and advice from development partners from corporate and academic research institutions around the world. In addition, the web interface has been designed by experts in human-computer interaction. The look and feel has been streamlined to make searching easier and provide a clear visualization of the results.
The result is a solution that goes beyond retrieving data.
Search results reflect how chemists think and work, helping their workflow move seamlessly from initial search, recognition of possible starting materials and their properties and through planning a strategy for the synthesis of a new compound to proposing a detailed synthetic route. Most compounds in Reaxys can be identified by their CAS Registry Numbers(R).
Migrating from Crossfire to Reaxys
Reaxys is available today and existing CrossFire customers may use Reaxys in parallel for an interim period. Elsevier offers full training and helpdesk support for new customers as well as guidance for the migration from CrossFire to the new platform. For the time being all CrossFire products as well as the Commander interface will be fully supported.
Select customers have been evaluating Reaxys throughout its development and have provided positive feedback. Elsevier will continue to engage with the chemistry community in future product development. For more information, visit http://www.info.reaxys.com.
About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com/), MD Consult (http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/), bibliographic databases, and online reference works.
Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Reaxys(TM) and CrossFire Beilstein are owned and protected by Elsevier Properties SA and used under license.
More about the addition of CAS Registry Numbers(R) can be found in a recent agreement between CAS (Chemical Abstract Service) and Elsevier: http://www.info.reaxys.com/press_room.
Tom Reller (For U.S.)
Director, Corp. Relations
+1-212-462-1912
T.Reller@Elsevier.com
Emma Potter (Europe/Asia)
Kaizo Public Relations
+44-(0)20-3043-4191
EPotter@Kaizo.net
Contacts:
General Information:
Tom Reller Director, Corporate Relations
USA
Phone: 212-462-1912 E-mail this person Company Information: Name: Elsevier Address: 1600 John F Kennedy Blvd. City: Philadelphia State: PA ZIP: 19103 Country: USA Phone: 215-239-3900 http://www.elsevier.com
News provided by ThomasNet News® (TNN). TNN is a comprehensive source
of new and timely product information in the industrial marketplace. TNN supplies new product
information to the web sites, e-marketplaces and print publications that serve the
industrial marketplace. For press release submissions please go to
http://news.thomasnet.com/submitpr.html.
BY ACCESSING, BROWSING AND/OR USING THIS WEB SITE AND/OR ANY WEB SITES PROVIDED BY
ProductNews.com, YOU AGREE TO BE BOUND BY THE TERMS OF USE
AGREEMENT.
del.icio.us
DIGG
Facebook
Reddit
StumbleUpon
Twitter
![[Get Copyright Permissions]](http://license.icopyright.net/images/icopy-w.gif){kind=small}
